Patent application number | Description | Published |
20080265711 | Mechanical packaging of surface acoustic wave device for sensing applications - A method and apparatus, wherein a die is attached to a supporting base structure utilizing a rigid bond adhesive for a SAW (Surface Acoustic Wave) sensor. A rigid bond adhesive with a preferably high glass transition temperature (Tg) can be applied directly between the die and the die supporting structure in a pattern to eliminate time dependent gradual stress effects upon SAW sensor. The rigid bond adhesive can then be cured, which results in a high yield strength and a high young's modulus. The supporting base and the die material comprise a same co-efficient of thermal expansion in order to avoid die displacement over temperature. | 10-30-2008 |
20090165546 | WIRELESS AND BATTERYLESS SENSOR - A wireless and batteryless pressure sensor apparatus comprises of a SAW sensor and an antenna mounted on a printed circuit board. Optionally, and RFID tag in used in combination with the SAW sensor. A sensor antenna and a RFID antenna can be located on the printed circuit board such that the antennas communicate electrically with the sensor and the RFID device. The sensor can be interrogated utilizing a radio frequency, which is used to excite a SAW crystal inside the sensor. The interrogation signal causes the SAW to resonate wherein a resonant frequency changes with the pressure and temperature that is applied to the sensor. An interrogator can receive a return (echo) signal representing a change in SAW sensor properties (e.g., diaphragm change). A printed circuit board can be mounted on a stainless steel port and overpackaged with standard processes for hermetically sealing the sensor, or sensor and RFID device with at least one antenna. | 07-02-2009 |
20090167503 | WIRELESS AND BATTERYLESS SENSOR - The SAW sensor in a stainless steel button package having a diaphragm and mounted on a threaded port. Package can hermetically seal a sensor and RFID-antenna assemblies from media. Sensor diaphragm is exposable to media. Sensor and RFID antennas communicate electrically with SAW sensor and RFID device, respectively, for sensor measurements and identification. Antennas receive RF interrogation signal from a nearby interrogator/transceiver and send reflected RF signals back to the interrogator unit containing sensor measurement and sensor ID. TRF signal excites a SAW resonator inside the sensor and causes the SAW to resonate wherein resonant frequency changes with pressure and temperature applied to the sensor. Antennas could be printed circuit board antennas, helical antennas, loop antennas, any other commercially available off-the-shelf antennas or a combination of these. | 07-02-2009 |
Patent application number | Description | Published |
20100193398 | REUSABLE SAMPLE HOLDING DEVICE PERMITTING READY LOADING OF VERY SMALL WET SAMPLES - A reusable sample-holding device for readily loading very small wet samples for observation of the samples by microscopic equipment, in particular in a vacuum environment. Embodiments may be used with a scanning electron microscope (SEM), a transmission electron microscope (TEM), an X-ray microscope, optical microscope, and the like. For observation of the sample, embodiments provide a thin-membrane window etched in the center of each of two silicon wafers abutting to contain the sample in a small uniform gap formed between the windows. This gap may be adjusted by employing spacers. Alternatively, the thickness of a film established by the fluid in which the sample is incorporated determines the gap without need of a spacer. To optimize resolution each window may have a thickness on the order of 50 nm and the gap may be on the order of 50 nm. | 08-05-2010 |
20110220840 | Fluid Viscosity and Heat Transfer Via Optimized Energizing of Multi-Walled Carbon Nanotube-Based Fluids - In select embodiments of the present invention, a method for optimizing thermal transfer capacity of a fluid employs multi-walled carbon nano-tubes (MWCNTs) and a surfactant such as Gum Arabic (GA), that are mixed into a fluid, such as water, according to a specific protocol and energized via ultrasound until a specified amount of total energy is applied. For select embodiments, the maximum demonstrated enhancement of an aqueous fluid in thermal conductivity is 20% and in convective heat Transfer is 32%. The thermal conductivity enhancement increased considerably at bulk temperatures greater than 24° C. The percentage enhancement in convective heat transfer in a tube increases with axial distance. The resultant optimized fluid is also described. | 09-15-2011 |
20120017415 | METHOD OF USE OF REUSABLE SAMPLE HOLDING DEVICE PERMITTING READY LOADING OF VERY SMALL WET SAMPLES - A method for using a reusable sample-holding device for readily loading very small wet samples for observation of the samples by microscopic equipment, in particular in a vacuum environment. The method may be used with a scanning electron microscope (SEM), a transmission electron microscope (TEM), an X-ray microscope, optical microscope, and the like. For observation of the sample, the method provides a thin-membrane window etched in the center of each of two silicon wafers abutting to contain the sample in a small uniform gap formed between the windows. This gap may be adjusted by employing spacers. Alternatively, the thickness of a film established by the fluid in which the sample is incorporated determines the gap without need of a spacer. To optimize resolution each window may have a thickness on the order of 50 nm and the gap may be on the order of 50 nm. | 01-26-2012 |
20130171401 | MESO-SCALE CARBON NANOTUBE SELF-ASSEMBLED TUBE STRUCTURES - Multiple-scale self-assembled tube structures (SATS) comprising multiwall carbon nanotubes (CNT) and processes for their nucleation and growth. These hierarchical and self-assembled SATS demonstrate the feasibility of controlled synthesis of macroscopic CNT structures and CNT-reinforced materials for use in broad applications such as structures, thermal transfer, electronics, fluid dynamics, and micro-fluidics. | 07-04-2013 |
20150050208 | Enzyme-Mediated Assimilation of DNA-Functionalized Single-Walled Carbon Nanotubes (SWNTs) - Select embodiments of the present invention employ biological means to direct assemble CNT-based nanostructures, allowing for scaling to macrostructures for manufacture. In select embodiments of the present invention, a method is provided for assembling DNA-functionalized SWNTs by phosphodiester bonding catalyzed by ssDNA-ligase to form macroscopic CNT aggregates. | 02-19-2015 |
Patent application number | Description | Published |
20100247635 | PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME - A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake. | 09-30-2010 |
20100278921 | SOLID ORAL FORMULATION OF ABT-263 - An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-04-2010 |
20100280031 | LIPID FORMULATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-04-2010 |
20100297194 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-25-2010 |
20150314000 | Pharmaceutically Acceptable Solubilizing Composition and Pharmaceutical Dosage Form Containing Same - Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake. | 11-05-2015 |
Patent application number | Description | Published |
20090105267 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES - The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antagonists, and are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole N-oxide compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein. | 04-23-2009 |
20100081715 | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof a other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically ceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 04-01-2010 |
20100280055 | Flavoring Systems for Pharmaceutical Compositions and Methods of Making Such Compositions - A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed. | 11-04-2010 |
20100323020 | STABLE NANOPARTICULATE DRUG SUSPENSION - A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D | 12-23-2010 |
20110091423 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV - The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof. | 04-21-2011 |
20120046360 | FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 02-23-2012 |
20120178808 | FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 07-12-2012 |
20120277190 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR - Compounds of formula (I) | 11-01-2012 |
20130252985 | Flavoring Systems for Pharmaceutical Compositions and Methods of Making Such Compositions - A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed. | 09-26-2013 |
20150259374 | TYLOSIN A ANALOGS AND DERIVATIVES - The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions. | 09-17-2015 |